Pharmacological Treatment of Unipolar Depression

Current Topics in Behavioral Neurosciences

Volumn 14, Issue , 2013, Pages 263-289

  Anderson, Ian M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antidepressants; Depression; Efficacy; Safety; Tolerability; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM SALT; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENELZINE; PINDOLOL; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; BLURRED VISION; CLINICAL PRACTICE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL STRESS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSOCIAL CARE; QT INTERVAL; QUALITY OF LIFE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; SWEATING; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS;

EID: 84880057483     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2012_208     Document Type: Review

References (98)

1. Adli M, Baethge C, Heinz A et al (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387-400
2. Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57:161-178
3. Anderson IM (2003) Drug treatment of depression: Reflections on the evidence. Adv Psychiatr Treat 9:11-20
4. Anderson I (2009) Commentary on STAR*D: A summary and UK perspective. J Psychopharmacol 23:613-614
5. Anderson IM, Haddad PM (2011) Prescribing antidepressants for depression: time to be dimensional and inclusive. Br J Gen Pract 61:50-52
6. Anderson IM, Ferrier IN, Baldwin RC et al (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343-396
7. Andrews PW, Kornstein SG, Halberstadt LJ et al (2011) Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2:159 Epub 7 Jul 2011
8. Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106(Suppl):S109-S113
9. Baldwin DS, Stein DJ, Dolberg OT et al (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? an exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269-275
10. Ban TA (2001) Pharmacotherapy of mental illness-a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry 25:709-727
11. Barr LC, Heninger GR, Goodman W et al (1997) Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41:949-954
12. Bauer M, Adli M, Bschor T et al (2010) Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62:36-42
13. Blier P, Ward HE, Tremblay P et al (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281-288
14. Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925-1932
15. Brunoni AR, Tadini L, Fregni F (2010) Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. PLoS One 5:9479
16. Carrasco JL, Sandner C (2005) Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 59:1428-1434
17. Cipriani A, Furukawa TA, Salanti G et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758
18. Corya SA, Williamson D, Sanger TM et al (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatmentresistant depression. Depress Anxiety 23:364-372
19. Curry J, Silva S, Rohde P et al (2011) Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 68:263-269
20. Eyding D, Lelgemann M, Grouven U et al (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737. doi:10.1136/bmj.c4737
21. Fava M, Rush AJ, Wisniewski SR et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161-1172
22. Food and Drug Administration (2011) FDA Drug Safety Communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Safety Announcement [08-24-2011]. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm
23. Fountoulakis KN, Moller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405-412
24. Fournier JC, DeRubeis RJ, Hollon SD et al (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47-53
25. Friedman ES, Anderson IM (2010) Managing depression in clinical practice. Springer-Verlag, London
26. Gartlehner G, Hansen RA, Morgan LC et al (2011) Comparative benefits and harms of secondgeneration antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155:772-785
27. Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-661
28. Gelenberg AJ, Thase ME, Meyer RE et al (2008) The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 69:1513-1528
29. Guzzetta F, Tondo L, Centorrino F et al (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68:380-383
30. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339
31. Hawton K, Bergen H, Simkin S et al (2010) Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 196:354-358
32. Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621-631
33. Holtzheimer PE, Mayberg HS (2011) Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34:1-9
34. Keers R, Uher R, Huezo-Diaz P et al (2011) Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 11:138-145
35. Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152-3160
36. Kennedy SH, Andersen HF, Thase ME (2009) Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25:161-175
37. King M, Nazareth I, Lampe F et al (2005) Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA 293:1089-1099
38. Kirsch I, Moncrieff J (2007) Clinical trials and the response rate illusion. Contemp Clin Trials 28:348-351
39. Kirsch I, Deacon BJ, Huedo-Medina TB et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:e45
40. Kocsis JH, Leon AC, Markowitz JC et al (2009) Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 70:354-361
41. Lin P, Campbell DG, Chaney EF et al (2005) The influence of patient preference on depression treatment in primary care. Ann Behav Med 30:164-173
42. McCabe C, Mishor Z, Cowen PJ et al (2010) Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67:439-445
43. McGrath PJ, Stewart JW, Fava M et al (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531-1541
44. McIntyre RS, Muzina DJ, Adams A et al (2009) Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 10:3061-3075
45. Melander H, Salmonson T, Abadie E et al (2008) A regulatory Apologia-a review of placebocontrolled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623-627
46. Mergl R, Henkel V, Allgaier AK et al (2011) Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? results from a randomized controlled trial including a patients' choice arm. Psychother Psychosom 80:39-47
47. Middleton H, Moncrieff J (2011) 'They won't do any harm and might do some good': time to think again on the use of antidepressants? Br J Gen Pract 61:47-49
48. Moller HJ, Bitter I, Bobes J et al (2012) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry 27:114-128
49. Moncrieff J (2006) Why is it so difficult to stop psychiatric drug treatment? it may be nothing to do with the original problem. Med Hypotheses 67:517-523
50. Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev CD003012
51. National Institute for Health and Clinical Excellence (2009a) Clinical guideline 90. Depression in adults (update): full guideline. http://guidance.nice.org.uk/CG90/Guidance
52. National Institute for Health and Clinical Excellence (2009b) Clinical guideline 91. Depression in adults with a chronic health problem: Full guideline. http://guidance.nice.org.uk/CG91
53. Newnham EA, Hooke GR, Page AC (2010) Progress monitoring and feedback in psychiatric care reduces depressive symptoms. J Affect Disord 127:139-146
54. Nierenberg AA, McLean NE, Alpert JE et al (1995) Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-1503
55. Nierenberg AA, Farabaugh AH, Alpert JE et al (2000) Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423-1428
56. Nierenberg AA, Fava M, Trivedi MH et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519-1530
57. Nutt DJ (2009) Beyond psychoanaleptics-can we improve antidepressant drug nomenclature? J Psychopharmacol 23:343-345
58. Opbroek A, Delgado PL, Laukes C et al (2002) Emotional blunting associated with SSRI-induced sexual dysfunction: do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 5:147-151
59. Papakostas GI, Shelton RC, Smith J et al (2007a) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826-831
60. Papakostas GI, Thase ME, Fava M et al (2007b) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227
61. Papakostas GI, Fava M, Thase ME (2008a) Treatment of SSRI-resistant depression: a metaanalysis comparing withinversus across-class switches. Biol Psychiatry 63:699-704
62. Papakostas GI, Nelson JC, Kasper S et al (2008b) A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 18:122-127
63. Papakostas GI, Charles D, Fava M (2010) Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebocontrolled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 11: 300-307
64. Portella MJ, de Diego-Adelino J, Ballesteros J et al (2011) Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 72:962-969
65. Posternak MA, Zimmerman M (2005) Is there a delay in the antidepressant effect? a metaanalysis. J Clin Psychiatry 66:148-158
66. Posternak MA, Zimmerman M (2007) Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 190(287-92):287-292
67. Pratt L, Brody D, Gu Q (2011) Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS data brief, no 76. National Center for Health Statistics, Hyattsville. http:// www.cdc.gov/nchs/data/databriefs/db76.htm
68. Preskorn SH (2010) CNS drug development: part I: the early period of CNS drugs. J Psychiatr Pract 16:334-339
69. Preskorn SH (2011) CNS drug development: part III: future directions. J Psychiatr Pract 17: 49-52
70. Price J, Cole V, Goodwin GM (2009) Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 195:211-217
71. Quitkin FM, Petkova E, McGrath PJ et al (2003) When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160:734-740
72. Rubino A, Roskell N, Tennis P et al (2007) Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334:242
73. Rudolph RL, Fabre LF, Feighner JP et al (1998) A randomized, placebo-controlled, doseresponse trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122
74. Ruhe HG, Huyser J, Swinkels JA et al (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836-1855
75. Ruhe HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331-359
76. Rush AJ (2007) STAR*D: what have we learned? Am J Psychiatry 164:201-204
77. Rush AJ, Trivedi MH, Wisniewski SR et al (2006a) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917
78. Rush AJ, Trivedi MH, Wisniewski SR et al (2006b) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242
79. Rush AJ, Trivedi MH, Stewart JW et al (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689-701
80. Serretti A, Chiesa A (2009) Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29:259-266
81. Shelton RC, Williamson DJ, Corya SA et al (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66:1289-1297
82. Simon GE, Perlis RH (2010) Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167:1445-1455
83. Simon GE, Savarino J (2007) Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 164:1029-1034
84. Sinyor M, Levitt AJ, Cheung AH et al (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? results from pooled and meta-analyses. J Clin Psychiatry 71:270-279
85. Smith D, Dempster C, Glanville J et al (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180(396-404):396-404
86. Stone M, Laughren T, Jones ML et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US food and drug administration. BMJ 339:b2880. doi:10.1136/bmj.b2880
87. Szegedi A, Jansen WT, van Willigenburg AP et al. (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6562 patients. J Clin Psychiatry 70:344-353
88. Tanti A, Belzung C (2010) Open questions in current models of antidepressant action. Br J Pharmacol 159:1187-1200
89. Thase ME, Shelton RC, Khan A (2006) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standardand higher-dosing strategies. J Clin Psychopharmacol 26:250-258
90. Thase ME, Friedman ES, Biggs MM et al (2007) Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 164:739-752
91. Thase ME, Larsen KG, Kennedy SH (2011) Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 199:501-507
92. Trivedi MH, Rush AJ, Crismon ML et al (2004) Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61: 669-680
93. Trivedi MH, Fava M, Wisniewski SR et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243-1252
94. Turner EH, Matthews AM, Linardatos E et al (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252-260
95. Uher R, Maier W, Hauser J et al (2009) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194:252-259
96. Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864
97. Zhong H, Haddjeri N, Sanchez C (2012) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter-a review of current understanding of its mechanism of action. Psychopharmacology 219:1-13
98. Zimmerman M, McGlinchey JB, Posternak MA et al (2006) How should remission from depression be defined? the depressed patient's perspective. Am J Psychiatry 163:148-150